Genertec Universal Medical Group Company Limited (5UM) - Net Assets
Based on the latest financial reports, Genertec Universal Medical Group Company Limited (5UM) has net assets worth €22.82 Billion EUR (≈ $26.68 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€85.72 Billion ≈ $100.21 Billion USD) and total liabilities (€62.90 Billion ≈ $73.53 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Genertec Universal Medical Group Company to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €22.82 Billion |
| % of Total Assets | 26.62% |
| Annual Growth Rate | 16.86% |
| 5-Year Change | 52.82% |
| 10-Year Change | N/A |
| Growth Volatility | 10.55 |
Genertec Universal Medical Group Company Limited - Net Assets Trend (2016–2024)
This chart illustrates how Genertec Universal Medical Group Company Limited's net assets have evolved over time, based on quarterly financial data. Also explore Genertec Universal Medical Group Company (5UM) total assets for the complete picture of this company's asset base.
Annual Net Assets for Genertec Universal Medical Group Company Limited (2016–2024)
The table below shows the annual net assets of Genertec Universal Medical Group Company Limited from 2016 to 2024. For live valuation and market cap data, see market value of Genertec Universal Medical Group Company.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €22.87 Billion ≈ $26.74 Billion |
+12.28% |
| 2023-12-31 | €20.37 Billion ≈ $23.81 Billion |
+3.37% |
| 2022-12-31 | €19.70 Billion ≈ $23.03 Billion |
+11.80% |
| 2021-12-31 | €17.62 Billion ≈ $20.60 Billion |
+17.76% |
| 2020-12-31 | €14.97 Billion ≈ $17.50 Billion |
+11.29% |
| 2019-12-31 | €13.45 Billion ≈ $15.72 Billion |
+31.11% |
| 2018-12-31 | €10.26 Billion ≈ $11.99 Billion |
+37.33% |
| 2017-12-31 | €7.47 Billion ≈ $8.73 Billion |
+13.60% |
| 2016-12-31 | €6.57 Billion ≈ $7.69 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Genertec Universal Medical Group Company Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €18.85 Billion | 100.00% |
| Total Equity | €18.85 Billion | 100.00% |
Genertec Universal Medical Group Company Limited Competitors by Market Cap
The table below lists competitors of Genertec Universal Medical Group Company Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Xiangtan Electrochemical Scientific Co Ltd
SHE:002125
|
$1.41 Billion |
|
IRB Infrastructure Developers Limited
NSE:IRB
|
$1.41 Billion |
|
Hotel101 Global Holdings Corp. Class A Ordinary Shares
NASDAQ:HBNB
|
$1.41 Billion |
|
ZWSOFT Guangzhou Co Ltd
SHG:688083
|
$1.41 Billion |
|
Iluka Resources Limited
F:ILZ
|
$1.41 Billion |
|
Sitio Royalties Corp.
NYSE:STR
|
$1.41 Billion |
|
Shanghai GenTech Co Ltd
SHG:688596
|
$1.41 Billion |
|
Shenzhen Sunline Tech Co Ltd
SHE:300348
|
$1.40 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genertec Universal Medical Group Company Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 17,350,174,000 to 18,853,737,000, a change of 1,503,563,000 (8.7%).
- Net income of 2,103,957,000 contributed positively to equity growth.
- Dividend payments of 615,139,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €2.10 Billion | +11.16% |
| Dividends Paid | €615.14 Million | -3.26% |
| Other Changes | €14.74 Million | +0.08% |
| Total Change | €- | 8.67% |
Book Value vs Market Value Analysis
This analysis compares Genertec Universal Medical Group Company Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.06x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €4.35 | €0.61 | x |
| 2018-12-31 | €5.85 | €0.61 | x |
| 2019-12-31 | €6.49 | €0.61 | x |
| 2020-12-31 | €7.24 | €0.61 | x |
| 2021-12-31 | €7.81 | €0.61 | x |
| 2022-12-31 | €8.26 | €0.61 | x |
| 2023-12-31 | €9.17 | €0.61 | x |
| 2024-12-31 | €9.97 | €0.61 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genertec Universal Medical Group Company Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.16%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.40%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 4.56x
- Recent ROE (11.16%) is below the historical average (13.28%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 13.27% | 32.30% | 0.09x | 4.41x | €214.87 Million |
| 2017 | 15.38% | 33.60% | 0.09x | 5.05x | €401.80 Million |
| 2018 | 13.46% | 31.47% | 0.09x | 4.70x | €347.36 Million |
| 2019 | 14.26% | 23.30% | 0.12x | 5.19x | €474.17 Million |
| 2020 | 14.06% | 20.50% | 0.14x | 4.95x | €504.85 Million |
| 2021 | 13.19% | 19.65% | 0.14x | 4.73x | €471.15 Million |
| 2022 | 12.55% | 16.47% | 0.15x | 4.92x | €398.36 Million |
| 2023 | 12.16% | 15.46% | 0.17x | 4.63x | €375.32 Million |
| 2024 | 11.16% | 15.40% | 0.16x | 4.56x | €218.58 Million |
Industry Comparison
This section compares Genertec Universal Medical Group Company Limited's net assets metrics with peer companies in the Credit Services industry.
Industry Context
- Industry: Credit Services
- Average net assets among peers: $4,894,927,676
- Average return on equity (ROE) among peers: 9.33%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genertec Universal Medical Group Company Limited (5UM) | €22.82 Billion | 13.27% | 2.76x | $1.41 Billion |
| Yiren Digital Ltd (19YA) | $2.97 Billion | 46.19% | 1.53x | $122.70 Million |
| Qudian Inc (1QU) | $11.69 Billion | 0.33% | 0.07x | $236.46 Million |
| Yixin Group Limited (1YX) | $16.48 Billion | 4.91% | 1.95x | $1.60 Billion |
| CREDIT CORP. GROUP LTD. (2RC) | $740.64 Million | 13.60% | 0.32x | $444.96 Million |
| HANHUA FNCL HLDG CO.H YC1 (5HF) | $7.93 Billion | 0.40% | 0.66x | $11.63 Million |
| PREMIA FINANCE O.N. (81U) | $3.47 Million | 0.23% | 0.46x | $1.64 Million |
| SY HOLDINGS GROUP HD-01 (9U0) | $3.95 Billion | 10.40% | 1.23x | $1.10 Billion |
| ALBIS Leasing AG (ALG) | $32.04 Million | 14.11% | 6.28x | $60.62 Million |
| Brockhaus Capital Management AG (BKHT) | $254.92 Million | -6.23% | 1.41x | $171.34 Million |
About Genertec Universal Medical Group Company Limited
Genertec Universal Medical Group Company Limited, together with its subsidiaries, provides financing, advisory, and medical services in the People's Republic of China. It operates through two segments, Finance Business and Healthcare Business. The Finance Business segment offers direct finance leasing; sale and leaseback; accounts receivable factoring; operating leases; and advisory services. Its… Read more